Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L.

Afiliação

Wang T; Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.
McAuslane N; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Goettsch WG; Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.
Leufkens HGM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
De Bruin ML; National Health Care Institute, Diemen, Netherlands.

Front Pharmacol ; 13: 948161, 2022.

Article em En | MEDLINE | ID: mdl-35924050

Palavras-chave

company strategies; drug development; evidence generation; health technology assessment (HTA); reimbursement; target product profile (TPP); value proposition

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_technology_assessment / Prognostic_studies / Qualitative_research Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google